Testing HIV vaccine in efficacy trials has begun in South Africa

hivResearchers have begun testing an HIV vaccine in efficacy trials for the first time in seven years, with the hope to provide at least partial immunity against the virus.

The study (HVTN 702) is currently being conducted in South Africa to test an updated version of an experimental vaccine developed by researchers at the US National Institute of Allergy and Infectious Diseases (NIAID), which had previously shown to have around 32% efficacy in an earlier trial (RV144). Continue reading

First Gene-Editing Human Trial Conducted in China

dna-163466_640China has used Crispr/Cas9 gene-editing technology to edit the DNA of a human subject that was suffering from metastatic lung cancer. The method used, will enable scientists to cut out a piece of DNA from living cell for modification and subsequently boost the immune system by injecting modified cells back into the body.

The study conducted by a team of scientist at West Hospital in Chendu, allowed for the cells of a patient suffering from metastatic non-small-cell lung cancer to be edited and then cultured to produce more cells before being injected back into the body. The cells that were Crispr-modified were white blood cells that had the potential to boost the immune system’s defences for fighting cancer. Continue reading

Clinical Professional’s Training Academy: Have We Found a Cure for the Plague…?

Clinical Professionals Group CEO, Yvette Cleland, comments on the “growing plague” currently affecting the life science industry:

Approximately a year and a half ago, Clinical Professionals launched their Life Sciences Academies, with the aim to fully fund, train and then support 12 months of CPD for some of the UK’s brightest life sciences graduates, many of which now have debts in the region of circa 50K on leaving university. However, the life sciences industry continues to offer huge barriers to entry, consistently asking for “3 years’ experience” for CTA’s and CRA’s. Where exactly does the Pharma/CRO industry think that experiences come from? Around 15 years ago when the world started being outsourced, pharma simply stopped investing in training and development for entry level staff. CRO’s have never picked up the pace in this area whilst managing continuing margin erosion. Continue reading

CPIA Report – Procurement

cpindustryanalyticscoverThe Clinical Professionals Group aim to provide candidates and clients with the best career advice and knowledge on recruitment by being attentive and responsive to the latest changes within life sciences.

Our desire to be at the forefront of analysis and reporting allow us to provide the best service to all who conduct business with us, which in turn enables us to aid sectors within the life science industry to evolve and progress for many years to come. Continue reading

Clinical Professionals Halloween Charity Update

halloween-1743239_640In the spirit of Halloween, the Clinical Professionals Group held a spooky themed Halloween day to help motivate our employees to obtain targets whilst raising money for the Arrows Group Foundation.

Employees took part in a number of spooky themed activities, including a themed board game where positive relationship building with candidates and clients gave CP employees points, which could then be traded in for health packs, weapons and dice rolls in order to navigate the treacherous board to the end prize. A ghastly lucky dip which involved participants digging into buckets of “brains” and “guts” with the chance of winning rewards, a fancy-dress competition and a spooky bake sale. Continue reading

UCB Launch New Self Injector in the UK for anti-inflammatory drug

ucb-svgUCB have announced the launch of a new pre-filled self-injecting device for its anti-inflammatory drug Cimzia in the UK, which was originally designed in collaboration with patients.

The firm says the AutoClicks Prefilled Pen has been cleared by UK regulators to administer the TNF inhibitor in all approved indications – rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis and axial spondyloarthritis. Which will allow dose administration in four simple steps. Continue reading

Eli Lilly Launch Initiative to Improve Healthcare Access for Millions

eli_lilly_logoLilly has recently announced their goal to expand global access to healthcare for 30 million people in resource-limited locations by 2030. The scheme, known as Lilly 30×30, is a new five-year, $90 million investment in the Lilly Global Health Partnership, to improve access to treatment for diabetes, cancer and tuberculosis.

One half of the $90 million commitment will come from the Eli Lilly and Company Foundation; the other portion will come from company funds. Continue reading

Clinical Professionals Sept 2016 Training Academy

sept_training_academyAt the Clinical Professionals Group, we strive to not only be innovative, but also proactive and our Training Academy is just one of the many services we provide as a service to the Life Science Industry.

The Academy was first initiated towards the end of 2014, as a result of witnessing the lack of newly trained candidates to fill the large quantity of entry level roles available within the life science industry, and in particular the clinical research sector. Continue reading

Scientific Professionals Website is Now Live

scientific-professionals-square-logoClinical Professionals are delighted to announce the launch of the new Scientific Professionals’ website!

Scientific Professionals, part of the Clinical Professionals Group was formed in response to focus on the needs of clients by finding key hires for their business. We pride ourselves on generating and maintaining successful, honest and professional partnerships with all of our contacts. Continue reading

BMS and Nektar Therapeutics announce oncology clinical collaboration

bms_logoBristol-Myers Squibb Company and Nektar Therapeutics have announced a new clinical collaboration to evaluate combining Bristol-Myers Squibb’s Opdivo with Nektar’s investigational medicine, NKTR-214, as a potential treatment regimen in five different tumour types and seven potential indications. Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression. Whilst NKTR-214 is an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting T cells and natural killer (NK) cells directly in the tumour micro-environment and increase expression of PD-1 on these immune cells. Continue reading